HealthStream, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are primarily with FY2020. This is an annual filing, not a standalone fourth-quarter report. HealthStream provides subscription software and related services for healthcare workforce training, development, scheduling, credentialing, privileging, and provider enrollment through Workforce Solutions and Provider Solutions.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $256.7 million (+5%) | $244.8 million |
| Gross margin | 64.5% | 63.5% |
| Operating income | $8.1 million; 3.1% margin | $15.8 million; 6.5% margin |
| Net income | $5.8 million | $14.1 million |
| Diluted EPS | $0.18 | $0.44 |
| Adjusted EBITDA (non-GAAP) | $52.7 million (+15%) | $46.0 million |
| Cash from operating activities | $42.4 million | $35.9 million |
- Workforce Solutions revenue rose 4% to $205.4 million; Provider Solutions revenue rose 9% to $51.3 million. Subscription services generated $243.6 million, about 95% of revenue.
- Cash, cash equivalents, and marketable securities totaled $51.9 million at year-end. Working capital was positive $6.5 million, versus negative $4.7 million a year earlier.
- No debt was outstanding. The company had a $65.0 million revolving facility fully available, subject to covenants; it reported compliance with all covenants. The facility matures October 2023.
- Operating cash flow increased 18%, primarily on higher collections; days sales outstanding improved to 50 from 51. Investing activities used $25.7 million and financing activities used $6.2 million.
Material changes and notable items
- Revenue growth included $27.2 million from recent acquisitions, net of acquired deferred-revenue write-downs, and growth in other solutions. These gains more than offset a $34.9 million decline in legacy resuscitation revenue, which fell to $3.5 million.
- Despite higher revenue and gross margin, operating income fell 49%. Product development expense increased $9.4 million, depreciation and amortization increased $6.6 million, and other operating costs also affected results. Other income shifted to a $0.3 million loss from $2.0 million of income in 2020.
- HealthStream acquired ComplyALIGN in January and Rievent in December 2021 for a combined approximately $6.0 million in cash. It reported approximately 5.04 million contracted hStream subscriptions, up from 4.22 million.
- The company repurchased 203,284 shares for $5.1 million under a new $20 million authorization. It does not anticipate regular cash dividends.
- In December, the CEO contributed shares valued at $2.25 million for fully vested employee awards; the company recorded corresponding stock-based compensation expense.
Outlook, risks, and contingencies
- Management gave no specific numerical revenue or earnings guidance in the provided filing text. It expects pandemic-related delays and reductions in customer bookings and renewals to pressure revenue and earnings in 2022 and potentially beyond. It also expects travel and trade-show costs to rise as activity normalizes, potentially before related revenue returns.
- Management said existing cash and investments, operating cash generation, and available credit should fund anticipated needs for at least 12 months and the foreseeable future. Remaining performance obligations were disclosed as $451 million, with approximately 47% expected to be recognized in 2022.
- Key risks include continuing COVID-19 effects on healthcare customers, delayed implementations and sales cycles, customer non-renewals, competition, talent shortages and wage inflation, cybersecurity and privacy exposure, and integration and impairment risks from acquisitions. Inflation may increase costs while many multiyear contracts do not automatically adjust fees.
- Goodwill was $182.5 million; management’s 2021 qualitative assessment found reporting-unit fair values substantially above carrying values, with no impairment recorded. Legal proceedings were not expected by management to have a material adverse effect. The filing’s financial statements and internal-control audits received unqualified opinions; Rievent was excluded from management’s year-end internal-control assessment because it had been acquired shortly before year-end.
Investor facts to verify
- Whether customer bookings, renewals, and implementation timing improved after the pandemic-related delays management expects to affect 2022 results.
- How much of reported revenue growth and adjusted EBITDA depends on acquisitions and non-GAAP adjustments, and whether acquired businesses deliver expected returns.
- Whether the $34.9 million legacy resuscitation revenue decline has stabilized and how recurring subscription growth offsets it.
- Whether the $451 million remaining-performance-obligation disclosure and 47% expected 2022 recognition reconcile to later filings and reported revenue.
- How product-development investment, amortization, stock-based compensation, repurchases, and any future borrowing affect operating profitability and per-share results.